X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
secukinumab (508) 508
index medicus (247) 247
psoriasis (247) 247
double-blind (188) 188
humans (183) 183
dermatology (160) 160
efficacy (130) 130
safety (123) 123
ustekinumab (118) 118
rheumatology (107) 107
arthritis (103) 103
psoriatic arthritis (96) 96
antibodies, monoclonal - therapeutic use (88) 88
ixekizumab (88) 88
psoriasis - drug therapy (86) 86
male (76) 76
interleukin-17 (75) 75
female (74) 74
adalimumab (73) 73
ankylosing spondylitis (73) 73
il-17 (69) 69
treatment outcome (69) 69
interleukin-17 - antagonists & inhibitors (68) 68
brodalumab (67) 67
plaque psoriasis (64) 64
severe plaque psoriasis (64) 64
etanercept (63) 63
clinical trials (62) 62
cytokines (62) 62
monoclonal-antibody (60) 60
adult (59) 59
middle aged (59) 59
moderate (59) 59
care and treatment (55) 55
monoclonal antibodies (51) 51
interleukins (50) 50
medicine & public health (50) 50
rheumatoid-arthritis (50) 50
biologics (49) 49
infliximab (46) 46
antibodies, monoclonal - adverse effects (45) 45
inflammation (45) 45
patients (44) 44
controlled-trial (43) 43
pharmacology & pharmacy (43) 43
placebo-controlled trial (42) 42
animals (41) 41
anti-interleukin-17a monoclonal-antibody (41) 41
disease (41) 41
pathogenesis (41) 41
apremilast (40) 40
spondyloarthritis (40) 40
tumor necrosis factor-tnf (40) 40
analysis (38) 38
interleukin-17 - immunology (38) 38
immunology (37) 37
interleukin-17a (36) 36
phase-iii (36) 36
severity of illness index (36) 36
th17 cells (35) 35
dermatologic agents - therapeutic use (34) 34
double-blind method (34) 34
drug therapy (34) 34
antibodies, monoclonal - administration & dosage (33) 33
psoriatic-arthritis (33) 33
quality of life (33) 33
therapy (33) 33
psoriasis - immunology (32) 32
il-17a (30) 30
interleukin 17 (30) 30
internal medicine (30) 30
medicine, general & internal (30) 30
ankylosing-spondylitis (29) 29
arthritis, psoriatic - drug therapy (29) 29
skin (29) 29
rheumatoid arthritis (28) 28
studies (28) 28
axial spondyloarthritis (27) 27
cells (27) 27
medicine, research & experimental (27) 27
abridged index medicus (26) 26
methotrexate (26) 26
research (26) 26
t-cells (26) 26
tumor necrosis factor (26) 26
antibodies, monoclonal, humanized - therapeutic use (25) 25
interleukin-12/23 monoclonal-antibody (25) 25
medicine (24) 24
management (23) 23
quality-of-life (23) 23
treatment (23) 23
inflammatory diseases (22) 22
phase-ii (22) 22
review (22) 22
tnf inhibitors (22) 22
to-severe psoriasis (22) 22
antirheumatic agents - therapeutic use (21) 21
il-23 (21) 21
tofacitinib (21) 21
open-label (20) 20
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (485) 485
German (9) 9
Russian (9) 9
French (5) 5
Korean (3) 3
Czech (2) 2
Portuguese (2) 2
Spanish (2) 2
Polish (1) 1
Slovak (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Annals of the Rheumatic Diseases, ISSN 0003-4967, 10/2017, Volume 76, Issue 10
Journal Article
British Journal of Dermatology, ISSN 0007-0963, 10/2018, Volume 179, Issue 4, pp. 811 - 812
Linked Article: Ryan et al. Br J Dermatol 2018; 179:844–852. 
SECUKINUMAB | DERMATOLOGY | Psoriasis
Journal Article
Clinical and Experimental Rheumatology, ISSN 0392-856X, 01/2018, Volume 36, Issue 1, pp. 50 - 55
Objective Secukinumab, a fully human anti-IL-17A monoclonal antibody, provided rapid and sustained improvements in signs and symptoms of ankylosing spondylitis... 
Secukinumab | Ankylosing spondylitis | Safety | SPONDYLOARTHRITIS | CELLS | RHEUMATOLOGY | safety | ankylosing spondylitis | secukinumab
Journal Article
Journal of the European Academy of Dermatology and Venereology, ISSN 0926-9959, 01/2019, Volume 33, Issue 1, pp. e22 - e23
Journal Article
Dermatology Online Journal, ISSN 1087-2108, 03/2018, Volume 24, Issue 3
Psoriasis is one of the most frequently occurring chronic inflammatory skin diseases. There are some specialized regions of the body that are considered... 
Secukinumab | Palmoplantar | Psoriasis | Scalp
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 12/2015, Volume 373, Issue 26, pp. 2534 - 2548
Journal Article
Rheumatology, ISSN 1462-0324, 04/2019, Volume 58, Issue 4, pp. 617 - 627
Abstract Objectives Synovial mast cells contain IL-17A, a key driver of tissue inflammation in SpA. A recent in vitro study showed that tissue-derived mast... 
IL-17A | mast cells | anti-IL-17A therapy (secukinumab) | FC-EPSILON-RI | SECUKINUMAB | RELEVANCE | RELEASE | RHEUMATOLOGY | INHIBITOR | EXPRESSION | IL-6
Journal Article
Dermatologica Sinica, ISSN 1027-8117, 2019, Volume 37, Issue 3, pp. 129 - 133
Background/Objective: Secukinumab is an effective treatment for psoriasis, and it has been reported to be effective in patients who failed on multiple prior... 
Adalimumab | psoriasis | secukinumab
Journal Article
Case Reports in Dermatology, ISSN 1662-6567, 09/2019, Volume 11, Issue 1, pp. 4 - 10
Kaposi’s varicelliform eruption (KVE) is a disseminated cutaneous infection usually induced by herpesvirus type 1 or 2, vaccinia virus or Coxsackie A16 virus... 
Psoriasis | Secukinumab | Herpes simplex virus
Journal Article
Case Reports in Dermatology, ISSN 1662-6567, 09/2019, Volume 11, Issue 1, pp. 29 - 37
Psoriasis (PsO) has been associated with obesity, and its severity increases in obese subjects. The link between psoriatic condition and obesity is based on... 
Obesity | Secukinumab | Psoriasis | Psoriatic arthritis
Journal Article
Case Reports in Dermatology, ISSN 1662-6567, 09/2019, Volume 11, Issue 1, pp. 23 - 28
Upon the association of biologic treatments with reactivation of latent tuberculosis infection (LTBI), screening for Mycobacterium tuberculosisinfection and... 
Psoriasis | Latent tuberculosis infection | Secukinumab
Journal Article
Therapeutic Advances in Musculoskeletal Disease, ISSN 1759-720X, 6/2013, Volume 5, Issue 3, pp. 141 - 152
Clinical and experimental evidence suggest that interleukin-17A (IL-17A; also known as IL-17) is an attractive therapeutic target in rheumatoid arthritis (RA).... 
interleukin-17A | methotrexate | rheumatoid arthritis | secukinumab | Reviews
Journal Article
NATURE COMMUNICATIONS, ISSN 2041-1723, 03/2016, Volume 7
Immune responses are crucial not only for host defence against pathogens but also for tissue maintenance and repair after injury. Lymphocytes are involved in... 
RESPONSES | SECUKINUMAB | MULTIDISCIPLINARY SCIENCES | IL-17 | HOST-DEFENSE | DOUBLE-BLIND | PROLIFERATION | ANTI-INTERLEUKIN-17A MONOCLONAL-ANTIBODY | DIFFERENTIATION | ARTHRITIS | EXPRESSION
Journal Article
British Journal of Dermatology, ISSN 0007-0963, 09/2019, Volume 181, Issue 3, pp. 624 - 626
Journal Article
Inflammation and Allergy - Drug Targets, ISSN 1871-5281, 2012, Volume 11, Issue 2, pp. 159 - 168
Journal Article
Journal of Dermatological Treatment, ISSN 0954-6634, 12/2018, Volume 29, Issue 2, pp. 3 - 4
Patients with psoriasis may be at higher risk of Candida spp. infection. Interleukin (IL)-17 acts in the prevention of those infections; it is also involved in... 
Secukinumab | psoriasis | Candida infection | DERMATOLOGY
Journal Article
Modern Rheumatology, ISSN 1439-7595, 2018, pp. 1 - 9
Secukinumab, a fully human monoclonal antibody that neutralizes interleukin-17A, improved the signs and symptoms of ankylosing spondylitis (AS) in three Phase... 
interleukin-17A | MEASURE 2-J | Japan | Ankylosing spondylitis | secukinumab
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.